With a full recovery rate of up to 92% in patients with acute lymphocytic leukaemia, clinical trials have produced very encouraging results. The effective application of CAR T-cell therapy to solid tumours and the associated clinical experience are constrained despite these promising results in haematological cancers because of therapeutic barriers like CAR T-cell expansion, persistence, trafficking, and fate within tumours.
When used in CAR T-cell therapies, T cells from the patient's blood are altered in the lab by the addition of a gene for a receptor (known as a chimeric antigen receptor, or CAR), which aids the T cells in adhering to a particular cancer cell antigen. After that, the patient receives their CAR T cells once more.
Read More:
https://cmitoc.blogspot.com/2022/11/car-t-cell-therapy-is-become-useful-in.html
